Induction of tumor-specific cytotoxicity by doxorubicin, and relation to the expression of mdr1 mRNA

被引：0
|
作者：
Sakagami, H
Suzuki, F
Hashimoto, K
Kikuchi, H
Nishikawa, H
Satoh, K
Kawase, M
Sunaga, K
Tsuda, T
机构：
[1] Meikai Univ, Sch Dent, Dept Dent Pharmacol, Kawagoe, Saitama 3500283, Japan
[2] Meikai Univ, Sch Dent, Dept Endocrinol, Kawagoe, Saitama 3500283, Japan
[3] Showa Univ, Sch Med, Dept Ana, Tokyo 1428555, Japan
[4] Josai Univ, Fac Pharm Sci, Kawagoe, Saitama 3500295, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2005年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：147P / 147P
页数：1
相关论文
共 50 条
  • [21] MDR1 expression in ocular melanoma
    Dunne, B
    McNamara, M
    Kennedy, SM
    LABORATORY INVESTIGATION, 1996, 74 (01) : 581 - 581
  • [22] Induction of MDR1 expression in normal rat and human intestine in vivo.
    Lown, KS
    Kolars, JC
    Ghosh, M
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A344 - A344
  • [23] Expression of MDR1 and MDR2 mRNA in human derived breast cancer cell lines.
    Killey, J
    Nicholl, AJ
    Garner, C
    Saul, MW
    Alalami, O
    Martin, JH
    BRITISH JOURNAL OF CANCER, 1999, 80 : 40 - 40
  • [24] ABCB1 MDR1) inherited polymorphisms in relation to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer
    Gligorov, J.
    Selle, F.
    Levy, E.
    Beerblock, K.
    Saintigny, P.
    Avenin, D.
    Rezai, K.
    Uzan, S.
    Antoine, M.
    Levy, P.
    Lokiec, F.
    Fajac, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S168 - S168
  • [25] Catalytic DNA and RNA for targeting MDR1 mRNA
    Kuznetsova, M
    Fokina, A
    Lukin, M
    Repkova, M
    Venyaminova, A
    Vlassov, V
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2003, 22 (5-8): : 1521 - 1523
  • [26] Induction and targeting of tumor-specific CTL
    Podack, ER
    Nishio, M
    Savaraj, N
    Spielman, J
    Casselith, PA
    Heike, Y
    Ohe, Y
    Saijo, N
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 1996, 21 (01) : 85 - 86
  • [27] Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells
    Chen, Bryan Wei
    Chen, Wei
    Liang, Hui
    Liu, Hao
    Liang, Chao
    Zhi, Xiao
    Hu, Li-qiang
    Yu, Xia-Zhen
    Wei, Tao
    Ma, Tao
    Xue, Fei
    Zheng, Lei
    Zhao, Bin
    Feng, Xin-Hua
    Bai, Xue-li
    Liang, Ting-bo
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (08) : 1805 - 1815
  • [28] Transthyretin mRNA is upregulated in mdr1 knockout mice
    Krohn, M.
    Mostertz, J.
    Boehm, M.
    Homuth, G.
    Voelker, U.
    Peters, M.
    Walker, L. C.
    Warzok, R. W.
    Vogelgesang, S.
    ACTA NEUROPATHOLOGICA, 2007, 114 (03) : 317 - 317
  • [29] LOWER MDR1 MRNA EXPRESSION IN HEPATIC FETAL AND PEDIATRIC TISSUE COMPARED TO ADULTS
    Mooij, M. G.
    De Wildt, S. N.
    De Koning, B. A.
    Schwarz, U. I.
    Tibboel, D.
    Kim, R. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S63 - S64
  • [30] Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression
    Zhou, Jia-Jia
    Deng, Xiao-Geng
    He, Xiao-Yu
    Zhou, Yu
    Yu, Min
    Gao, Wen-Chao
    Zeng, Bing
    Zhou, Quan-Bo
    Li, Zhi-Hua
    Chen, Ru-Fu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (06) : 2034 - 2040
12345